20 publications
Name | Date | Type | Actions |
---|---|---|---|
2010 annual earnings Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements. |
04/04/2011 | Public releases | |
2010 Revenues grow 11.8%, driven by organic growth The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth. |
25/01/2011 | Public releases | |
2021 Annual results ALL FINANCIAL INDICATORS UP. |
24/03/2022 | Public releases | |
2022 HALF YEAR RESULTS Sales: €271m (up 6.0% as reported) |
15/09/2022 | Public releases | |
2022 HALF YEAR RESULTS Additional information on the Group’s strategy Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook. |
23/09/2022 | Public releases , Half Year Report | |
Availability of the 2021 universal registration document Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022. |
22/04/2022 | Public releases | |
Double-digit growth in 2021 Total Group Sales: €521 million (up 21.9% as reported) |
20/01/2022 | Public releases | |
European launch of new Nsaid Cimalgex® Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs. |
14/06/2011 | Public releases | |
First nine months 2022 sales: €405M In line with year-end outlook |
12/10/2022 | Public releases | |
Forcyl®: european launch of new drug Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection. |
29/09/2011 | Public releases |